Eli
Eli Lilly Endorses Trump’s Goal by Raising Drug Prices Abroad to Align with U.S. Levels
Eli Lilly; drug prices; Donald Trump; international pricing; Mounjaro; U.K.; Europe; pharmaceutical tariffs; Project 2025
Eli Lilly and Superluminal Ink $1.3B Pact Targeting GPCRs in Obesity, Cardiometabolic Diseases
Eli Lilly; Superluminal Medicines; GPCRs; obesity drugs; cardiometabolic diseases; AI drug discovery; MC4R; partnership; milestones; equity investment
Lilly’s Q2 2025 Beat-and-Raise Overshadowed by Orforglipron Data
Eli Lilly; Q2 2025 earnings; orforglipron; oral GLP-1; weight loss; obesity franchise; regulatory submission; analyst expectations
Lilly Posts Encouraging Early-Stage Weight Loss Data on Amylin Candidate
Eli Lilly; eloralintide; amylin candidate; weight loss; early-stage trial; obesity drug; clinical data; side effects
Eli Lilly Strikes $650M Deal with Juvena to Develop Muscle-Boosting Drugs
Eli Lilly; Juvena Therapeutics; muscle-boosting drugs; AI drug discovery; muscle health; biotech collaboration; stem cell secreted proteins; drug development; obesity management; $650 million deal
Eli Lilly Expands RNA Pipeline with $1.3 Billion Rznomics Hearing Loss Pact
Eli Lilly; Rznomics; RNA editing; hearing loss; gene therapy; pharmaceutical partnerships; biotech; trans-splicing ribozyme; sensorineural hearing loss; RNA therapeutics
Lilly backs $65M raise for biotech plumbing the ‘dark genome’ with AI
Haya, Eli Lilly, Genome, Long Intergenic Non-Protein Coding RNA, Obesity, Aortic Valve Insufficiency, Eli, Dark color
Compounders just lost their case to put obesity drug tirzepatide back in shortage
Tirzepatide, compounding, FDA, drug shortage, Eli Lilly, Zepbound, Mounjaro, legal case, Outsourcing Facilities Association (OFA), GLP-1 medications
Eli Lilly licenses early-stage ALS drug program from Alchemab in $415M pact
Amyotrophic Lateral Sclerosis, Alchemab, Eli, Eli Lilly
Lilly taps Creyon’s AI-enabled oligo tech in heavily backloaded $1B deal
Creyon, Eli Lilly, Eli, Oligonucleotides